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Effect of Allopurinol on phosphocreatine recovery and muscle function in older people 
with impaired physical function – a randomised controlled trial 
Abstract 
Background 
Allopurinol has vascular antioxidant effects and participates in purinergic signalling within 
muscle. We tested whether allopurinol could improve skeletal muscle energetics and physical 
function in older people with impaired physical performance.  
Methods 
We conducted a randomised, double blind, parallel group, placebo-controlled trial, comparing 
20 weeks of allopurinol 600mg once daily versus placebo. We recruited community-dwelling 
participants aged 65 and over with baseline six-minute walk distance of <400m and no 
contraindications to MRI scanning. Outcomes were measured at baseline and 20 weeks. The 
primary outcome was post-exercise phosphocreatine recovery rate measured using 31P 
magnetic resonance spectroscopy of the calf. Secondary outcomes included six-minute walk 
distance, short physical performance battery (SPPB), lean body mass measured by 
bioimpedance, endothelial function and quality of life.  
Results 
124 participants were randomised, mean age 80 (SD 6) years. 59 (48%) were female, baseline 
six-minute walk distance was 293m (SD 80m) and baseline SPPB was 8.5 (SD 2.0). 
Allopurinol did not significantly improve phosphocreatine recovery rate (treatment effect 
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0.10 units [95%CI -0.07 to 0.27], p=0.25). No significant changes were seen in endothelial 
function, quality of life, lean body mass or SPPB. Allopurinol improved six-minute walk 
distance (treatment effect 25m [95% 4 to 46, p=0.02]). This was more pronounced in those 
with high baseline oxidative stress and urate.  
 
Conclusion 
Allopurinol improved six-minute walk distance but not phosphocreatine recovery rate in 
older people with impaired physical function. Antioxidant strategies to improve muscle 
function for older people may need to be targeted at subgroups with high baseline oxidative 
stress. 
Trial registration: ISRCTN03331094 
 
 




- Oxidative stress has been implicated in muscle dysfunction and allopurinol has been 
shown to reduce oxidative stress in other organ systems with clinical benefit. 
- Allopurinol did not improve phosphocreatine recovery rate (a measure of skeletal 
muscle mitochondrial function) 
- Six-minute walk distance improved by a small but clinically significant amount but 
other measures of physical performance were unchanged 




Impaired physical performance is common with increasing age, and reduction in skeletal 
muscle function (part of the syndrome of sarcopenia) is a key contributor to this decline. 
Improving impaired physical function and preventing decline in physical function are key 
goals in maintaining health and wellbeing for a wide range of older people. Although regular 
exercise has been shown to increase muscle strength and to slow functional decline [1], the 
majority of older people are sedentary and often unable or unwilling to contemplate adequate 
exercise participation [2]. Alternative strategies to improve physical function are required to 
minimise dependency and maximise independence.  
Allopurinol is a purine analogue which has been used to prevent gout for decades. It is a 
powerful inhibitor of xanthine oxidoreductase in both its forms – as xanthine dehydrogenase 
and as xanthine oxidase (XO). Inhibition of this key enzyme in the degradation of purines to 
urate lowers both urate as well as reactive oxygen species (ROS) which is a by-product of 
XO catalytic action. There are three reasons why allopurinol might be beneficial in ageing 
muscle. Firstly, skeletal muscle is particularly susceptible to oxidative stress mainly due to 
the rapid flux of oxygen and the balance of energy supply/demand. Previous studies have 
shown that oxidative stress is implicated in reduced quadriceps endurance [3]. Xanthine 
oxidase is a major generator of free radicals; up-regulation of xanthine oxidase and increased 
oxidative stress are found in ageing muscles and this mechanism has been implicated in 
sarcopenia [4]. Therefore reducing muscle oxidative damage might be expected to result in 
reduced muscle dysfunction, increased muscle contractile efficiency and reduced functional 
impairment. 
Secondly, animal studies have previously demonstrated that allopurinol decreased free ADP 
levels needed to drive ATP synthesis, and normalised muscle phosphocreatine (PCr)-to-ATP 
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ratio (PCr/ATP) [5]. These findings would be compatible with a beneficial effect of 
allopurinol on mitochondrial function, perhaps due to the reduction in oxidative stress 
described above. Suppression of Xanthine Oxidase (XO) with allopurinol has indeed been 
shown to increase maximal isometric force in plantar flexion in animal models [6], and 
allopurinol use was associated with greater functional gains in older patients undergoing 
rehabilitation in an observational study [7].  
Thirdly, we have previously shown that allopurinol improves vascular endothelial function in 
various intervention studies enrolling older people with established cardiometabolic disease 
[8-11]. An improvement in muscle perfusion could also potentially improve muscle function, 
particularly given the high prevalence of vascular dysfunction found in older people. 
Therefore, we conducted this present study in older people with functional impairment to 
determine whether treatment with allopurinol could improve physical function, and to study 
the mechanism by which it might achieve this. We hypothesised that allopurinol would 
improve the initial rate of skeletal muscle phosphocreatine recovery after exercise (a measure 




We performed a randomised, double-blinded, parallel-group, placebo-controlled trial between 
February 2016-August 2017. Ethics approval was obtained from East of Scotland Research 
Ethics committee (approval number 14/ES/1092), and regulatory approval was obtained from 
the Medicines and Healthcare products Regulatory Agency (Clinical Trials Authorisation 
2014-004122-18). It was carried out in accordance with the declaration of Helsinki. Written 
informed consent was obtained from all participants at the screening visit. The trial was 
funded by Dunhill Medical Trust (Grant Ref: R315/1113) and trial management support was 
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provided by Tayside Clinical Trials Unit. The trial was registered at www.isrctn.com 
(ISRCTN03331094). 
 
Population and recruitment 
Participants were eligible if they were aged 65 or over, with a six minute walk distance of 
<400m based on the study conducted by Newman et al [12]. Exclusion criteria were 
conditions likely to provide alternative causes for poor exercise tolerance and muscle 
dysfunction: a documented history of peripheral arterial disease, severe heart failure (left 
ventricular ejection fraction <35%), malignancy under active treatment, severe COPD, or 
long-term use of steroids (prednisolone equivalent of 10mg/day or more). Other exclusion 
criteria were for safety reasons: intolerance to allopurinol, any use of allopurinol within the 
last 30 days, current use of azathioprine, 6-mercaptopurine or theophyllines, or an estimated 
Glomerular Filtration Rate (eGFR) of 30ml/min/1.73m2 or less. Participants unable to 
perform the short physical performance battery or six minute walk tests without human 
assistance were excluded, as were those with contraindications to MRI scanning, cognitive 
impairment precluding giving written informed consent, those who had participated in 
another clinical drug trial within the preceding 30 days and those with active acute gout. 
Participants were recruited via hospital outpatient clinics, newspaper advertisements to the 
local community, and from primary care practice database searches conducted by the NHS 
Research Scotland Primary Care Network (NRSPCN). 
 
Intervention and comparator 
Matching capsules containing either 300mg of allopurinol or placebo that appeared identical 
(Tayside Pharmaceuticals, Dundee, UK) were dispensed in identical bottles which had no 
indication of treatment allocation. Participants took one capsule each day for the first four 
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weeks. If renal function remained stable and no side effects were noted, participants then took 
two capsules once a day for the remaining 16 weeks. Participants were permitted to continue 
their usual medication throughout the trial. 
 
Randomisation and allocation concealment 
Randomisation was performed in a 1:1 ratio by a web-based GCP compliant randomisation 
system (TRuST, Health Informatics Centre, University of Dundee) to ensure allocation 
concealment. A minimisation algorithm with a small random element was used to ensure 
balance across key baseline measures. Minimisation factors used were male vs female sex 
and baseline six-minute walk distance of < or >200m.  
 
Outcomes 
All outcomes were measured at baseline and at 20 weeks. Details of the methods used for 
outcomes measures are given in the Supplementary Information [13-20]. The pre-specified 
primary outcome was the initial rate of PCr recovery (ViPCR). Secondary outcomes were the 
six-minute walk distance [16], Short Physical Performance Battery [17], lean body mass 
derived from bioimpedance using the Sergi equation [18], endothelial function [19], and 
health-related quality of life measured using the EQ5D tool [20]. All outcomes were assessed 
by a research fellow blinded to intervention group, and investigators remained blinded to 
treatment allocation until after completion of the statistical analysis. 
 
Sample size calculation 
The sample size was calculated based on detecting a 20% difference between groups in the 
primary outcome of initial PCr resynthesis rate (ViPCR). Data published by Layec et al [3] 
showed ViPCr values in healthy older people (74±17 %/min) vs COPD patients (52±13 
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%/min) i.e. a 42% difference between healthy older people and patients with COPD. A 
conservative approach would be to assume that functionally impaired older people have less 
severe impairment than people with COPD. We therefore assumed 20% difference between 
healthy older people and functionally impaired older people on allopurinol. To detect this 
difference with 90% power at a significance level of α=0.05 requires 44 participants per 
group. Allowing for a 20% dropout rate, we required 110 participants. To ensure a further 
buffer against technical failure or uninterpretable MR spectroscopy results, the final sample 
size was set at 124 participants, which also gave sufficient power for key secondary 
endpoints to detect a 2% absolute difference in Flow-Mediated Dilatation of the brachial 
artery (FMD) [21] and the minimum clinically important difference of 20m for the six minute 
walk [22].  
 
Analysis 
All analyses were performed using SPSS v24 (IBM, New York, USA) according to a pre-
specified statistical analysis plan. A p value of <0.05 was taken as significant for all analyses. 
Descriptive statistics were generated for both groups at baseline; comparisons between 
baseline groups were performed using Student’s t-test for continuous variables if normally 
distributed, and Mann-Whitney U test for non-normally distributed variables. Categorical 
variables were compared using Pearson’s chi-square test. The primary and secondary 
analyses were performed by modified intention to treat, including all participants with 
follow-up data. For normally distributed variables, general linear models were used to 
compare results between groups at 20 weeks, adjusted for baseline values. Several of the 
MRS variables were not normally distributed, but instead conformed to a gamma distribution. 
These variables were compared using generalised linear models, adjusting for baseline values 
of the variable under test, using a gamma distribution and log link function. Estimated 
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marginal means were generated to convey treatment effect size. Several sensitivity analyses 
were performed for the primary outcome. Multiple imputation (10 imputations) was 
performed using baseline ViPCr, age, sex, baseline six-minute walk distance and SPPB to 
impute missing ViPCr values. A per-protocol analysis was also performed, including only 
those participants still taking the full dose of study medication at the final visit, and with 
adherence >80%. Statistical analyses were performed blinded to treatment allocation, and 
unblinding of the analysis took place only after analysis completion. 
 
Results 
265 individuals expressed interest in participating, of whom 142 attended a screening visit, 
and 124 were randomised. Baseline data on the randomised population are given in Table 1, 
and Figure 1 shows participant flow through the trial. A total of 116 individuals (58/62 in the 
allopurinol arm and 58/62 in the placebo arm) attended the final study visit. Adherence to the 
study medications was excellent; mean adherence in the allopurinol group was 93% (SD 
12%), compared to 95% (SD 12%) in the placebo group (p=0.32). 
 
Primary Outcome 
There was no significant difference between the allopurinol and placebo groups in the initial 
rate of PCr recovery (ViPCR) corrected for baseline ViPCr. (Table 2) 
 
Subgroup and sensitivity analyses: 
Pre-specified subgroup analyses for the primary outcome are shown in Supplementary Table 
1. The only significant subgroup interaction was with baseline six-minute walk distance, 
where those with the lowest walk distance (<200m) showed deterioration in ViPCr with 
treatment, in contrast to those with a baseline walk distance of >300m (p=0.05 for 
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interaction). For the per-protocol sensitivity analysis, a total of 98 participants were included 




Non-MRS secondary outcomes are shown in Table 3. Allopurinol caused a large reduction in 
serum urate compared to the placebo group as expected. Six minute walk distance improved 
in the allopurinol group compared to placebo; the treatment effect (25m) was statistically 
significant and exceeded the minimum clinically important difference of 20m. Post-hoc 
exploratory subgroup analyses of the six minute walk distance suggested that the difference 
in 6MWT was significantly greater in participants who had higher baseline muscle oxidative 
stress (8-OHDG > 233ng/ml) and baseline urate (>0.41mmol/L) (Supplementary Table 2). A 
weak correlation (rho=0.18, p=0.06) was seen between change in ViPCr and change in six-
minute walk distance. Other measures of oxidative stress, endothelial function, physical 
performance, lean body mass and quality of life did not improve with allopurinol relative to 
placebo. Alternative MRS measures of muscle energetics are shown in Supplementary Table 
3; no significant treatment effect was seen on any marker. 
 
Adverse events 
Adverse events are shown aggregated into MedDRA system-organ-class categories in 
Supplementary Table 4. More adverse events were seen in the allopurinol arm, driven by a 





The main finding from this present study is that allopurinol did not improve muscle 
efficiency as measured by initial rate of PCr recovery in older participants with functional 
impairment. However, it improved the 6MWT distance and this improvement was more 
pronounced in those with a higher baseline oxidative stress and urate level. This would 
suggest that the mechanism of improvement may not be by ADP-sparing and improved 
Phosphocreatine recycling but rather via an alternative antioxidant mechanism. We have 
previously demonstrated in a heart failure cohort that allopurinol at this high dose functions 
as an effective antioxidant, capable of abolishing Vitamin C-sensitive component of vascular 
oxidative stress [8]. Urate is an abundant and potent aqueous antioxidant in humans, although 
its importance as a major antioxidant in vivo is unclear [23,24]. It is possible that reducing 
urate in normouricemic patients with low background oxidative stress, who rely on urate for 
antioxidant defence, will negate any direct reduction in ROS generation by xanthine oxidase 
inhibition, leading to an overall null effect on oxidative stress, mitochondrial function and 
therefore PCr recovery. This could also explain the non-significant increase in 8OHDG we 
saw with treatment. This phenomenon has been previously demonstrated in another 
normouricemic cohort with low oxidative stress [25].  
 
We found an increase in the secondary outcome of 6-minute walk test distance of 25m in the 
allopurinol group compared to placebo. Perera et al [22] suggest that a 20m gain in 6MWT is 
the minimum meaningful change in older people. In this present study, this difference in 
6MWT was significantly greater in participants who had higher baseline muscle oxidative 
stress and baseline urate, which suggests that xanthine oxidase inhibition in these patients 
may be beneficial. The lack of effect of allopurinol on phosphocreatine recovery rate makes it 
unlikely that the improvement in six-minute walk distance was driven by improved 
mitochondrial function in normouricemic patients with low background oxidative stress. One 
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alternative explanation is that allopurinol may have exerted improvements in exercise 
capacity via adenosine receptors present in a variety of tissues including the heart and skeletal 
muscle; it is noteworthy that caffeine (a molecule in the xanthine family) is known to have 
beneficial effects on exercise capacity. It is also possible that the improvement in six-minute 
walk distance was a chance finding due to testing multiple secondary outcomes; this finding 
requires replication in future trials. 
 
Future studies in older people should focus interventions in those with high baseline 
oxidative stress and hyperuricemia. Unlike previous studies in cohorts with established 
disease [8,26], we did not observe an improvement in vascular endothelial function in this 
cohort which suggests that any functional improvement seen in this study is not directly 
attributable to improvements in muscle blood flow. Markers of ATP depletion such as the 
rate constant k, Pi/PCr ratio and amount of β-ATP depletion post-exercise were not 
significantly different between groups indicating that ATP sparing may not be the mechanism 
by which allopurinol improved walk distance. 
 
Limitations 
Preclinical work suggests that allopurinol might improve muscle function by reduction of 
XO-derived oxidative stress [6,27,28]. There are several reasons why we may not have 
detected this improvement in this present study. Only two men and no women met the 
clinical definition for sarcopenia and therefore it is possible that individuals with more 
impaired muscle physiology (i.e. those with sarcopenia) may have demonstrated greater 
improvement in muscle efficiency with allopurinol. The half-time recovery for 
phosphocreatine at baseline in our study was relatively preserved, suggesting that a ceiling 
effect may have limited the ability of allopurinol to improve measures of mitochondrial 
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function. A previous study showed that patients with sarcopenia have impaired endothelial 
function, a measure upon which allopurinol has repeatedly demonstrated a beneficial effect 
[29]. We deliberately used a high dose of allopurinol to be sure that XO-derived oxidative 
stress was completely abolished; previous dose-response work in patients with heart failure 
suggests that 600mg per day is required to achieve this [8]. The duration of therapy in our 
study was 20 weeks. It is possible but unlikely that a longer duration of action is required to 
demonstrate improvement in muscle efficiency if muscle oxidative stress reduction by XO 
inhibition is the mechanism by which it occurs. The positive effect on urate levels and 
improvement in six-minute walk distance argue in favour of this duration being long enough 
to produce relevant biological effects. Shorter durations of allopurinol therapy have shown 
improvements in endothelial function in previous studies [8,11], and as little as one week of 
allopurinol treatment improved skeletal muscle and mitochondrial function in preclinical 
models [6,30]. Muscle biopsies may have yielded more information on muscle oxidative 
stress but this option was declined by almost all patients and was therefore not pursued. Data 
acquisition for MR Spectroscopy commenced immediately post-exercise, potentially missing 
the very start of the recovery curve. Although we conducted the six-minute walk test only 
once at baseline and once at follow-up, the parallel-group design of our trial accounted for 
any learning effect, and thus the improvement in the allopurinol arm cannot be attributed to 
this.  
 
In this present study, treatment allopurinol over 20 weeks did not improve muscle energetics 
as measured by MR spectroscopy. We observed a clinically relevant but modest increase in 
the 6MWT. Future studies could prospectively target those with sarcopenia, high urate and 
baseline muscle oxidative stress. Such an approach would be most likely to maximise the 
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efficacy of allopurinol and would stand the best chance of both confirming any effect on walk 
distance and of elucidating the mechanism of any such effect. 
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Mean age (years) (SD) 79.9 (5.3) 80.6 (6.6) 0.55 
Female sex (%) 29 (47) 30 (48) 0.86 
Ischaemic heart disease (%) 8 (13) 12 (19) 0.33 
Hypertension (%) 42 (68) 33 (53) 0.10 
Dyslipidaemia (%) 34 (55) 33 (53) 0.86 
Stroke or TIA (%) 7 (11) 6 (10) 0.77 
Diabetes mellitus (%) 10 (16) 10 (16) 1.00 
Median weekly alcohol intake (units) 
(IQR) 
2 (1 – 8) 2 (0 – 5) 0.38 
Current smoker (%) 3 (5) 5 (8) 0.47 
Systolic blood pressure (mmHg) (SD) 141 (15) 146 (20) 0.14 
Diastolic blood pressure (mmHg) (SD) 78 (10) 76 (10) 0.49 
Body Mass Index (kg/m2) (SD) 28.5 (4.6) 28.1 (4.9) 0.59 
Six minute walk distance (m) 295 (80) 290 (79) 0.75 
Muscle mass (kg) (SD) Males 11.6 (2.3) 11.2 (2.4) 0.50 
Females 9.9 (1.8) 10.1 (1.6) 0.72 
Short physical performance battery (SD) 8.6 (2.0) 8.4 (2.0) 0.69 
Median total number of medications 
(IQR) 





Angiotensin converting enzyme inhibitor 15 (24) 17 (27) 0.68 
Beta blocker 9 (15) 12 (19) 0.47 
Calcium channel blocker 22 (35) 17 (27) 0.33 
Alpha blocker 7 (11) 5 (8) 0.76 
Thiazide 14 (23) 15 (24) 0.83 
Loop diuretic 5 (8) 5 (8) 1.00 
Aldosterone antagonist 2 (3) 2 (3) 1.00 
Angiotensin receptor blocker 6 (10) 5 (8) 0.75 
Statin 29 (47) 23 (37) 0.28 
Antiplatelet 14 (23) 16 (26) 0.68 
Insulin 2 (3) 0 (0) 0.50 
Antidiabetic 6 (10) 6 (10) 1.00 






Table 2. Primary outcome – effect of treatment on measures of phosphocreatine recovery rate 










Baseline 0.50 (0.33-0.83) 0.60 (0.35-0.78) 0.10  
(-0.07 to 0.27) 
0.25 
20 weeks 0.60 (0.33-0.94) 0.59 (0.43-0.82) 
      
Sensitivity analyses 
Normalised ViPCr – 
multiply imputed 
  0.08  
(-0.09 to 0.26) 
0.36 
  





Baseline 0.50 (0.31-0.99) 0.54 (0.32-0.76) 0.10  
(-0.07 to 0.27) 
0.27 
20 weeks 0.63 (0.36-0.96) 0.58 (0.43-0.82) 








20 weeks 28227 (16818-51171) 29005 (17810-42279) 
ViPCr: Initial rate of phosphocreatine recovery 
*Estimated marginal mean from generalised linear model using gamma distribution with log 
link 
Multiple imputation: using baseline ViPCr, age, sex, baseline six min walk and SPPB to 




Table 3. Secondary outcomes 







Six minute walk 
(m) 
Baseline 295 (80) 290 (79) 25 (4 to 46) 0.02 
20 weeks 366 (95) 340 (85) 
      
Lean body mass 
(kg/m2) 
Baseline 10.8 (2.3) 10.7 (2.1) 0.1 (-0.5 to 0.7) 0.70 
20 weeks 10.6 (2.0) 10.4 (2.0) 
      
SPPB Baseline 8.6 (2.0) 8.4 (2.0) 0.0 (-0.5 to 0.5) 0.91 
20 weeks 9.3 (1.8) 9.1 (1.9) 
      
EQ5D health 
state 
Baseline 0.78 (0.20) 0.77 (0.23) 0.02 (-0.03 to 0.07) 0.41 
20 weeks 0.81 (0.14) 0.80 (0.20)   
      
EQ5D 
thermometer 
Baseline 78 (15) 78 (14) 2 (-2 to 6) 0.32 
20 weeks 79 (14) 78 (13) 
      
Systolic BP 
(mmHg) 
Baseline 141 (15) 146 (20) 0 (-5 to 5) 0.94 
20 weeks 143 (15) 145 (17) 
      
Diastolic BP 
(mmHg) 
Baseline 78 (10) 76 (10) -1 (-4 to 2) 0.66 
20 weeks 76 (10) 76 (11) 
24 
 
      
FMD* (%) Baseline 7.50 (3.86) 7.59 (3.95) -0.63 (-2.11 to 0.84) 0.39 
20 weeks 6.92 (3.07) 7.45 (3.69) 
      
FMD GTN (%) Baseline 14.88 (5.55) 17.09 (5.50) 2.23 (-0.57 to 5.03) 0.12 
 20 weeks 16.37 (5.30) 15.25 (6.64) 
      
Urate (mmol/L) Baseline 0.38 (0.14) 0.42 (0.14) -0.12 (-0.16 to 0.08) <0.001 
20 weeks 0.24 (0.16) 0.40 (0.15) 
      
TBARS (uM) Baseline 2.94 (1.51) 3.09 (1.34) 0.09 (-0.38 to 0.56) 0.70 
20 weeks 3.10 (1.68) 3.18 (1.51) 
      
8OHDG Baseline 254 (107) 251 (104) 23 (-4 to 50) 0.10 
20 weeks 292 (140) 258 (104) 
8OHDG: 8-hydroxydeoxyguanosine. BP: Blood pressure. EQ5D: EuroQoL 5 dimension 
score. FMD: Flow-mediated dilatation of the brachial artery. GTN: Glyceryl trinitrate. SPPB: 
Short physical performance battery. TBARS: Thiobarbiturate Reactive Substances 
*n=43 for each group at baseline 





Figure 1: CONSORT diagram of participant flow through the trial 
 
